About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Florida | 10,975 Studies Near You | Clareo Health

Clinical Trials LocationsFlorida

Clinical Trials in Florida

Discover 10,975 clinical trials near Florida. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 1421-1440 of 10,975 trials

Active Not RecruitingPhase 249 miles

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

NCT07023835

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS)

Zydus Therapeutics Inc.240 participantsStarted Sep 2025

La Jolla, California, United States • Orange, California, United States • San Francisco, California, United States +14 more locations

RECRUITINGNA49 miles

Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs

NCT07222995

The purpose of this study is to examine how different messages about risk of skin cancer can impact the uptake of skin cancer prevention activities.

H. Lee Moffitt Cancer Center and Research Institute2,900 participantsStarted Oct 2025

Tampa, Florida, United States • New York, New York, United States

Find Trials by Condition in Florida

Breast Cancerin Florida Lung Cancerin Florida Prostate Cancerin Florida Colorectal Cancerin Florida Melanomain Florida Leukemiain Florida Lymphomain Florida Pancreatic Cancerin Florida Ovarian Cancerin Florida Brain Cancerin Florida Diabetes

Data from ClinicalTrials.govTerms

Active Not RecruitingPhase 249 miles

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

NCT06001385

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+8 more

Center for International Blood and Marrow Transplant Research313 participantsStarted Dec 2023

Phoenix, Arizona, United States • Scottsdale, Arizona, United States • Little Rock, Arkansas, United States +29 more locations

RECRUITING49 miles

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

NCT06218875

A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device) as a part of routine clinical practice.

AAA - Abdominal Aortic Aneurysm

W.L.Gore & Associates2,000 participantsStarted May 2024

Little Rock, Arkansas, United States • Irvine, California, United States • Los Angeles, California, United States +87 more locations

Active Not RecruitingPhase 349 miles

A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib

NCT03673501

This is a 2-arm, randomized, open-label, international, multicenter study comparing the efficacy of ripretinib to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 426 patients will be randomized in a 1:1 ratio to ripretinib 150 mg once daily (continuous dosing for 6 week cycles) or sunitinib 50 mg once daily (6 week cycles, 4 weeks on, 2 weeks off).

Gastrointestinal Stromal Tumors

Deciphera Pharmaceuticals, LLC453 participantsStarted Feb 2019

Scottsdale, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +118 more locations

RECRUITINGNA49 miles

The MIND-BC Study: MIND Diet for Breast Cancer Cognition

NCT07018986

This fully, powered efficacy RCT, the MIND diet for Breast Cancer Cognition (MIND-BC), will evaluate the MIND diet in a rigorous, highly controlled academic cancer center. We will recruit breast cancer survivors reporting CRCI with a MIND diet score \< 8, based on a previously devised 14-item diet questionnaire designed to detect inadequate diet with respect to brain health (scores range from 0 to 14, with lower scores indicating a less adequate diet).14 Breast cancer survivors will have recently completed adjuvant treatment (i.e., 6 months to three years previously), to ensure that perceived cognitive impairment is likely chronic and due to cancer. To achieve maximal effect, the study consists of two 12-week phases 1) intervention phase, 2) maintenance phase.

H. Lee Moffitt Cancer Center and Research Institute200 participantsStarted Jul 2025

Tampa, Florida, United States

COMPLETEDPhase 349 miles

Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease

NCT04049760

This is a long-term, Open-label Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Migalastat in Subjects \> 12 Years of Age With Fabry Disease and Amenable GLA Variants

Amicus Therapeutics16 participantsStarted Oct 2019

Tampa, Florida, United States • Atlanta, Georgia, United States • Minneapolis, Minnesota, United States +3 more locations

COMPLETED49 miles

Exploring Men s Prostate Cancer Genetic Risk Perceptions

NCT06764992

The exploring men's prostate cancer genetic risk perceptions and willingness to give a biospecimen for genetic risk testing study aims to assess prostate cancer genetic risk and susceptibility beliefs among unaffected men of diverse races/ethnicities who are considering undergoing prostate cancer screening and their willingness of men to provide a biospecimen (saliva sample) and test the samples for prostate cancer aggressiveness and determine risk category based on SNP genetic profile.

Prostate Cancer

H. Lee Moffitt Cancer Center and Research Institute100 participantsStarted Aug 2022

Tampa, Florida, United States

RECRUITINGPhase 249 miles

A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

NCT06524830

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.

Treatment Resistant Depression

atai Therapeutics, Inc.142 participantsStarted Dec 2024

Tucson, Arizona, United States • Little Rock, Arkansas, United States • Little Rock, Arkansas, United States +39 more locations

COMPLETEDPhase 296 miles

Efficacy and Safety of MK-8189 in Participants With an Acute Episode of Schizophrenia (MK-8189-008)

NCT04624243

The purpose of this study was to evaluate the efficacy and safety of MK-8189 at a range of doses (8 mg, 16 mg, and 24 mg once daily \[QD\]) in adult participants who have an acute episode of schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5) criteria. The primary hypotheses were the following: (1) that MK-8189 24 mg is superior to placebo in reducing the Week 6 mean change from baseline in Positive and Negative Syndrome Scale (PANSS) total score, and (2) that MK-8189 16 mg is superior to placebo in reducing the Week 6 mean change from baseline in PANSS total score. With Amendment 4, enrollment was changed to approximately 500 participants with removal of the MK-8189 8 mg treatment arm. Participants enrolled before Amendment 4 who were assigned to MK-8189 8 mg QD remained on that dose regimen per protocol.

Merck Sharp & Dohme LLC499 participantsStarted Dec 2020

Bentonville, Arkansas, United States • Little Rock, Arkansas, United States • Rogers, Arkansas, United States +118 more locations

COMPLETED135 miles

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

NCT02910557

A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.

MelanomaHerpetic Infection

Amgen187 participantsStarted Aug 2017

Coral Springs, Florida, United States • Baltimore, Maryland, United States • Jefferson City, Missouri, United States +20 more locations

RECRUITINGPhase 2136 miles

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

NCT06632600

This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.

Novartis Pharmaceuticals130 participantsStarted Apr 2025

Sylmar, California, United States • Gainesville, Florida, United States • Boston, Massachusetts, United States +15 more locations

TERMINATEDPhase 2139 miles

A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)

NCT05592275

The main purpose of this study is to assess the efficacy and safety of LY3540378 in adults with worsening heart failure with preserved ejection fraction

Heart FailureHeart Failure With Preserved Ejection Fraction

Eli Lilly and Company332 participantsStarted Feb 2023

Tucson, Arizona, United States • Covina, California, United States • Northridge, California, United States +134 more locations

COMPLETEDPhase 3148 miles

Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)

NCT03829319

The purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer. The primary study hypotheses state that: 1) the combination of lenvatinib + platinum doublet chemotherapy + pembrolizumab prolongs Progression-free Survival (PFS) as assessed by blinded independent central review (BICR) per modified Response Evaluation Criteria in Solid Tumors version 1.1 (RESIST 1.1) compared to matching placebo + platinum doublet chemotherapy + pembrolizumab, and 2) the combination of lenvatinib + platinum doublet chemotherapy + pembrolizumab prolongs Overall Survival (OS) compared to matching placebo + platinum doublet chemotherapy + pembrolizumab.

Nonsquamous Non-small Cell Lung Cancer

Merck Sharp & Dohme LLC761 participantsStarted Mar 2019

Mountain View, California, United States • New Haven, Connecticut, United States • Fort Lauderdale, Florida, United States +155 more locations

RECRUITINGPhase 1166 miles

A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)

NCT06655246

In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated previously with imatinib.

Gastrointestinal Stromal Tumor (GIST)Gastrointestinal Stromal CancerGastrointestinal Stromal Neoplasm+2 more

Kura Oncology, Inc.157 participantsStarted Mar 2025

Birmingham, Alabama, United States • Phoenix, Arizona, United States • La Jolla, California, United States +29 more locations

Active Not RecruitingPhase 2/3177 miles

A Study of AL102 in Patients With Progressing Desmoid Tumors

NCT04871282

The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.

DesmoidDesmoid Tumor

Immunome, Inc.198 participantsStarted Mar 2021

Pheonix, Arizona, United States • Duarte, California, United States • Santa Monica, California, United States +50 more locations

RECRUITING592 miles

International CRDS Registry

NCT06508164

Calcium Release Deficiency Syndrome (CRDS) is a newly discovered genetic arrhythmia syndrome that confers a risk of life-threatening arrhythmias secondary to RYR2 loss-of-function. The International CRDS registry has been designed to facilitate large-scale evaluation of CRDS, including its phenotypic spectrum, approaches to risk stratification, and optimal treatment strategies.

Calcium Release Deficiency Syndrome

Population Health Research Institute500 participantsStarted Nov 2024

San Francisco, California, United States • Rochester, Minnesota, United States • Durham, North Carolina, United States +13 more locations

COMPLETEDPhase 2/3719 miles

Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)

NCT03969901

The primary purpose of this study is to evaluate the safety and tolerability of imipenem/cilastatin/relebactam (IMI/REL) in participants from birth to less than 18 years of age with confirmed or suspected gram-negative bacterial infection. Participants are expected to require hospitalization through completion of intravenous (IV) study intervention, and have at least one of the following primary infection types: hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP); complicated intra-abdominal infection (cIAI); or complicated urinary tract infection (cUTI). Participants will be randomized in a 3:1 ratio to receive IMI/REL or active control. This study will also evaluate the efficacy of IMI/REL by assessing all-cause mortality at Day 28 post-randomization, as well as clinical and microbiological response to treatment. It will also evaluate the pharmacokinetics of IMI/REL.

Suspected or Documented Gram-negative Bacterial Infection

Merck Sharp & Dohme LLC115 participantsStarted Oct 2019

Tucson, Arizona, United States • Long Beach, California, United States • San Diego, California, United States +64 more locations

RECRUITINGPhase 1806 miles

An Investigational Study of BG-89894 Tablets in Participants With Advanced Solid Tumors

NCT06568614

This study is being done to learn more about a new drug called BG-89894 (previously known as SYH2039). Researchers want to see if the drug is safe, how well people can tolerate it, how it moves through the body, and whether it shows any early signs of helping to treat cancer. The information gathered may help guide how future studies are designed. The entire study is expected to last about four years. People who join the study may receive treatment for around six months and will be followed for about 12 months after their treatment ends. The study plans to enroll participants over a three-year period.

Advanced or Metastatic MTAP-deleted Solid Tumors

BeOne Medicines140 participantsStarted Oct 2024

Baltimore, Maryland, United States • St Louis, Missouri, United States • New York, New York, United States +17 more locations

RECRUITINGPhase 1839 miles

A Study of MGC026 in Participants With Advanced Solid Tumors

NCT06242470

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion of the study. Participants will receive MGC026 by intravenous (IV) infusion. The dose of MGC026 will be assigned at the time of enrollment. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood samples collected for research purposes.

Advanced Solid TumorAdvanced CancerMetastatic Cancer+19 more

MacroGenics250 participantsStarted Mar 2024

Los Angeles, California, United States • Grand Rapids, Michigan, United States • Lake Success, New York, United States +9 more locations

PreviousPage 72 of 549Next

in Florida

Heart Diseasein Florida